For patients with type 2 diabetes, GLP-1 RAs are associated with an increased risk for GERD and its complications compared with SGLT-2 inhibitors.

Estimated risk ratio was lower with GLP-1 receptor agonists for those younger than 75 years, but was no different for those aged 75 years or older ...

Company to Host Pre-Eminent Lap-Band® Surgeon Advocates For a Three-Day Seminar, August 1-3, 2025 ...

Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the ...

Gilles Andrier, CEO of Givaudan discusses HY earnings, and outlines areas of growth within the business despite ongoing ...

Low rates of retained gastric contents were seen in endoscopy patients on GLP-1 receptor agonists ( RAs), a retrospective ...

Coca-Cola is less exposed to the U.S. market’s weakness in snacks and soda, compared with other food and beverage companies.

The money will focus on a manufacturing plant in Virginia that will make the company's weight management and metabolic drugs ...

For older adults with diabetes, there is no clear evidence to suggest that the incidence of dementia differs for those using ...

More than one-third of people who helped develop the 2023 guidelines for treating children with obesity had undisclosed ...

Discover how food brands can adapt to the rising GLP-1 trend. As weight-loss drugs reshape consumer habits, learn which ...

Few things can jolt a pharmaceutical company's shares like positive results from highly anticipated clinical trials. Even so, ...